Skip to main content

Table 3 Clinical characteristics of the development cohort

From: Quantitative parameters of lymphocyte nuclear morphology in bronchoalveolar lavage fluid as novel biomarkers for sarcoidosis

  Sarcoidosis HP NSIP COP DILD CTD-ILD
Number of patients 18 16 5 5 14 10
Number of lymphocytes analyzed 872 751 253 249 706 637
Age 60.0 ± 3.8 70.9 ± 2.1 73.0 ± 3.0 65.0 ± 6.2 62.4 ± 2.5 61.2 ± 4.0
Gender(M/F) 6/12 12/4 3/2 4/1 11/3 3/7
Smoking (yes/no) 9/9 10/5 (NR: 1) 2/3 3/2 12/2 4/6
Total cell count (*104/ml) 2.12 ± 0.34 3.33 ± 0.76 2.07 ± 0.20 3.56 ± 0.92 2.51 ± 0.46 2.64 ± 0.33
Lymphocyte count (*105/ml) 7.13 ± 1.07 15.4 ± 4.17 8.15 ± 2.00 13.2 ± 4.08 11.9 ± 3.45 13.8 ± 2.94
Fraction of lymphocyte (%) 34.0 ± 2.67 42.0 ± 3.71 38.3 ± 6.09 37.6 ± 10.4 42.1 ± 3.62 50.8 ± 5.82
  1. HP, hypersensitivity pneumonia; NSIP, nonspecific interstitial pneumonia; COP, cryptogenic organizing pneumonia; DILD, drug-induced interstitial lung disease; CTD-ILD, connective tissue disease-associated interstitial lung disease; NR, not reported